What kind of treatment drug is neratinib/neratinib (He Li'an)?

Neratinib is an oral small molecule irreversible pan-HER inhibitor, mainly used to treat HER2-positive breast cancer. It is one of the important breakthroughs in the field of targeted therapy in recent years. Its core mechanism of action is to inhibit the HER1, HER2 and HER4 signaling pathways in the human epidermal growth factor receptor family, thereby blocking the proliferation and survival signals of tumor cells. Overexpression of HER2 (human epidermal growth factor receptor 2) is an important driving factor in the malignant progression of some breast cancers. Neratinib irreversibly binds to the kinase domain of HER2, continuously inhibiting downstream signaling pathways (such as MAPK and PI3K/Akt), fundamentally blocking the growth and invasion capabilities of cancer cells.

Neratinib has been approved by many countries for the extended adjuvant treatment of patients with early-stage HER2-positive breast cancer, especially those who have completed adjuvant treatment with trastuzumab, to reduce the risk of cancer recurrence. In addition, neratinib is also used in combination treatment regimens for some patients with advanced or metastatic HER2-positive breast cancer, and is often used in combination with drugs such as capecitabine to delay disease progression and improve survival benefits. Clinical experience shows that neratinib can significantly improve the disease-free survival (iDFS) of patients with HER2-positive early breast cancer, and it also has certain preventive significance for people at high risk of brain metastasis.

Different from traditional chemotherapy, neratinib is a molecularly targeted drug that does not directly kill normal cells, but inhibits the abnormal proliferation of cancer cells by targeting specific signaling pathways. The drug is already on the market in the United States, Europe and Japan under the trade name Nerlynx. The emergence of neratinib marks a new stage in the treatment of HER2-positive breast cancer from the era of single antibodies to combined, sequential and oral targeted therapy.

Reference materials:https://en.wikipedia.org/wiki/Neratinib